RecruitingGraves' Disease

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

Eligible age

18–75 yrs

Accepts

All genders

Locations

27 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment. The primary objective of this study is to evaluate the efficacy of IMVT-1402 versus placebo as assessed by T3 (total triiodothyronine \[T3\] or free triiodothyronine \[FT3\]), free thyroxine (FT4), thyroid-stimulating hormone (TSH), and ATD dose at Week 26.

Sponsor: Immunovant Sciences GmbH

You may qualify if…

✓ Participants with the ability to understand the requirements of the trial, provide written informed consent, and comply with the trial protocol procedures.
✓ Male or female participants aged ≥ 18 years.
✓ Participants with diagnosis of GD who are hyperthyroid despite ATD treatment.
✓ Other, more specific inclusion criteria are defined in the protocol.

You may not qualify if…

✕ Have previously been successfully treated with radioactive iodine (RAI) therapy or have undergone total thyroidectomy.
✕ Have an autoimmune disease other than GD requiring treatment that, in the Investigator's judgment, puts the participant at undue risk.
✕ Have moderate-to-severe active thyroid eye disease (TED) and are expected to require immediate surgical intervention and/or are planning corrective surgery/irradiation or medical therapy for TED during study participation.
✕ Additional exclusion criteria are defined in the protocol.